FTSJ1 source guide

FTSJ1 performs tRNA anticodon-loop ribose methylation. The central evidence distinguishes human proteins, patient cells, yeast complementation and mouse phenotypes.

• PMID:25404562 original: Results s2d–s2e, Methods s4b–s4e and Figures 5–6 captions show human FTSJ1 restoring Cm32 in yeast. Human FTSJ1 and human THADA were directly coexpressed in the yeast double-deletion host and restored Cm32. Gm remained undetectable; WDR6 complementation was inconclusive because expression was poor. This source does not positively assay human Gm34, although later human experiments establish that capacity.
• PMID:26310293 original: Methods S3–S9, Results S12–S17 and Figures 1–5 captions distinguish human patient-LCL HPLC from yeast Trm7 variant/partner experiments. Human A26P selectively loses Phe Gm while retaining Cm. The separate supplementary construct Methods/tables were not independently read. An earlier EuropePMC error did not prevent recovery of the authentic NCBI full XML.
• PMID:32558197 original: selected Results 2/3/5–8 and Methods 29 establish human FTSJ1-WDR6 Gm34 reconstitution, SAM binding and localization. The binary reaction does not form Cm32, and its negative Trp result is specific to the tested conditions. Figure 7 and its dual-luciferase Methods also show reduced UUU decoding in human HEK293T knockout cells; this is not a mouse-only translation result. Table 2/Figure 6 show cellular Um32 dependence in tRNAArg(CCG). Leu(CAA) C34 is supported through earlier work and was excluded from the new transcript screen. Tagged imaging/fractionation supports predominant cytoplasmic and smaller nuclear pools.
• PMID:33771871 original: selected human Results, HumanCells and Methods 15–18 establish patient tRNA isolation, rescue and fragment/nucleoside MS. Author supplementary PDF, S2 pages 3–4 and S3 page 5 caption, explicitly identifies FTSJ1-WDR6 C34 methylation of human Trp(CCA). Caption text was read; no pixel-level audit is claimed. Human patient-cell measurements additionally show Sec position 34 methylation dependence; a Sec-specific rescue or isolated Sec reaction was not established in the selected experiments. Brain ribosome-profiling and neural phenotypes are mouse evidence.
• PMID:36720500 original: Results s3/Table 2 and Methods s12/s14 show human patient-LCL RiboMethSeq. Phe Cm32 needs raw cleavage-profile inspection because adjacent modifications and reverse-transcription arrest confound MethScore. Results s7/Figure 4 and Methods s22–s28 show DAP-treated human developing neurons with more thin neurite protrusions but no significant difference in the DCX-positive differentiation fraction. The 100 micromolar, 24-hour human DAP assay lacks a genetic rescue and does not isolate every off-target effect. The positive neurite-protrusion endpoint supports refinement to neuron projection morphogenesis (GO:0048812). The paper's DCX-based neurogenesis measurement was unchanged; this null result does not negate every subprocess of neurogenesis, but the specific morphology term better matches the positive endpoint. Fly morphology and memory are separate experiments. No direct protein-synthesis assay is attributed to this paper.
• PMID:40483304 original: selected sections 3–6/9/14–15 and captions establish the human FTSJ1-THADA structure and coupled SAM-to-SAH activity assay. Structural C32 positioning and the fluorescence assay are distinct evidence layers; this is not direct site-resolved Cm32 MS. Missing density is not a natural deletion.
• PMID:32393790 original: selected Methods 2–6/8, Results 12/14–17 and Discussion 18 examine human NSCLC cells, bulk tRNA Am and DRAM1 expression. The authors explicitly did not assess protein synthesis. The translation annotation is marked as over-annotated because FTSJ1 performs preceding tRNA modification; the independent human reporter phenotype is retained without inventing an NSCLC translation assay or direct DRAM1 regulation.

The author-name correction, PMID:32488007, changes Yuhuan Chen to Yuchen Chen. Its complete short body states no experimental revision, retraction or replacement.

The HuRI original selected Methods and exact source-specific IntAct records support human FTSJ1–CERT1-2 association in yeast. Pair-specific mammalian validation, purified affinity and an exact FTSJ1 natural-product assignment are not established. HPA25 records supported cytosolic ICC/IF in A-431, U-251MG and U2OS; annotation and assay metadata were read, not image pixels.

The actual C32 Reactome reaction and G34 reaction identify FTSJ1 through their catalyst chains. Their cytosolic location is modeled by yeast homology and independently supported by human data. Both model records retain a THADA requirement, including G34. A structured source query identifies the G34 Requirement R-HSA-9024157 and THADA regulator R-HSA-8870282. The cached summary describes THADA for C32; the G34 edge was inspected in the actual ContentService model. C32 THADA support remains intact, and the G34 model is queried against the primary WDR6 result.

PTHR10920 contains the exact 329-aa human target at AN21/PTN002475051. All four incoming IBA assertions join literal positive IBDs at ancestor AN2/PTN000100323 with exact donor sets. Single-donor and self-donor evidence are not defects. Two non-target plant FASTA/alignment differences are retained in the phylogeny report and do not affect the exact human sequence. The family label does not establish an rRNA substrate.

UniProt documents 329-aa and 327-aa products; the latter is the exact 219–220 deletion. None of the selected experiments tests its functional consequences. Remaining bibliography-only sources carry individual access notes rather than a claim that their full texts were read. Normal-cache availability is distinct from independently accessed original text. No new annotation is proposed. Eight short exact-cache quotation occurrences now support the review follow-up; the immutable caches remain unchanged.

Genuine source and annotation mapping

The genuine acquisition contains 40 original GOA contexts, 40 exported TSV rows and 40 native annotation objects. Raw and native orders differ; the evidence archive retains every actual index and all 16 columns. The native seed is separately archived unchanged. Both 329/327-residue natural-product declarations and all original source identifiers, donors and qualifiers are preserved. No annotation extension or negation occurs.

The actual source set contains 29 files: 23 publications, three Reactome entries and three existing PANTHER sources. Fifteen exact main files were reused and 14 absent paths acquired. The four-file PTHR10920 directory, including its existing family review, remains unchanged; only its three source files belong to this gene's normal source set. The 16-row PAINT slice retains all four incoming ancestral assertions. Source metadata below does not claim that unread full texts or all supplementary experiments were inspected.

The follow-up preserves all 40 original machine assertions and the three established catalytic cores. Three translation judgments change to MARK_AS_OVER_ANNOTATED; the internal evidence archive now also has a manual reference assessment, for 35 assessed references. That translation/substrate follow-up recorded 20 ACCEPT, four KEEP_AS_NON_CORE, 13 TOO_GENERAL and three MARK_AS_OVER_ANNOTATED. The follow-up passed default validation, strict GOA reconciliation, the status audit and native history validation, with one retained generic-binding advisory and DRAFT status. The notes retain the earlier outcomes and record this follow-up separately.

The subsequent morphology refinement changes only the original neurogenesis review to MODIFY with GO:0048812. Current totals are 20 ACCEPT, three KEEP_AS_NON_CORE, 13 TOO_GENERAL, three MARK_AS_OVER_ANNOTATED and one MODIFY. All original source assertions and eight existing quotations are retained. The narrow follow-up passed default validation, strict GOA reconciliation, the status audit and native history validation. Status remains DRAFT with the same single generic-binding advisory.